Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret^®) Example.

Item request has been placed!

Item request cannot be made.

Processing Request

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

المؤلفون: Warren, Emma¹ (AUTHOR) ; Castles, Belinda J. C.² (AUTHOR); Sharratt, Gillian C.² (AUTHOR); Arteaga, Aitor² (AUTHOR)
المصدر:
Infectious Diseases & Therapy. Mar2024, Vol. 13 Issue 3, p549-564. 16p.

Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example.